Enhancing Therapeutic Strategies: A Focus on Pharmacovigilance in New Wave Antidepressants and Antipsychotics

2,927
Total downloads
14k
Total views and downloads

Articles

ORIGINAL RESEARCH

Accepted on 23 Jul 2025

Post marketing Safety Assessment of the Novel Postpartum Depression Drug, Zuranolone: Evidence from Real-World Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System (FAERS)

Duoqin Huang
Zixin Luo
Xi Gong
Kang Zou
Yu Peng

doi 10.3389/fpsyt.2025.1517773

567 views

ORIGINAL RESEARCH

Published on 14 May 2025

Evaluation of drug interactions in outpatients taking antipsychotic medications

Bshra A. Alsfouk
Qamar M. Aljanadi
Mona M. Almutairi

doi 10.3389/fphar.2025.1590167

1,319 views

BRIEF RESEARCH REPORT

Published on 05 Mar 2025

Patterns in (es)citalopram prescriptions to Medicaid and Medicare patients in the United States: the potential effects of evergreening

Luke R. Cavanah
Parita K. Ray
Jessica L. Goldhirsh
Leighton Y. Huey
Brian J. Piper

doi 10.3389/fpsyt.2025.1450111

940 views
1 citation

ORIGINAL RESEARCH

Published on 24 Feb 2025

Post-marketing safety surveillance of vortioxetine hydrobromide: a pharmacovigilance study leveraging FAERS database

Ying Zhang
Shengzhu Sun
Yunhong Ning

doi 10.3389/fpsyt.2025.1532803

1,947 views

CASE REPORT

Published on 07 Nov 2024

Vortioxetine as an alternative treatment for somatic symptom disorder: case report

Naoki Furutani
Yasuhide Nagoshi

doi 10.3389/fpsyt.2024.1496072

2,581 views
2 citations

REVIEW

Published on 25 Sep 2024

Exploring cariprazine as a treatment option for varied depression symptom clusters

Bojana Pejušković
Ana Munjiza Jovanović
Danilo Pešić

doi 10.3389/fpsyt.2024.1442699

4,001 views
1 citation

Share on

Frontiers in Psychiatry

Frontiers in Psychiatry

Psychopharmacology
Mood Disorders

Participating Journals

Frontiers in Pharmacology
- Translational Pharmacology
- 4.8 impact factor
- 8.9 citescore

Impact

14kTopic views
10kArticle views
2,927Article downloads